GGrantIndex
← Leaderboards

Ben H Park

Johns Hopkins University

Google Scholar ↗PubMed ↗ORCID ↗
$14,510,999
Attributed
$22,781,000
Total exposure
14
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $13.4M · FY2005–25
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$68,839,206 · 16

By mechanism

P30$43,585,909 · 5
P50$7,513,457 · 1
UH3$6,381,605 · 1
R01$5,176,742 · 4
T32$3,776,897 · 1
UG3$2,127,132 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsFutureResearch PersonnelLeadMalignant Breast NeoplasmProgramsBaseGenomicsCancer CenterCancer TherapyResource SharingResponseRecruitTechnologyTumorCessation Of LifeCancer PatientTranslational ResearchClinical TrialsEvaluationCollaborationsFundingInnovationBreast

Grant awards (67)

Cancer Center Support Grant$8,155,508
P30 · FY2025 · CA · contact PI
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan$2,201,003
UH3 · FY2025 · CA
Molecular Mediators of Cell-free DNA biogenesis$670,147
R01 · FY2025 · CA · contact PI
Developmental Funds$339,811
P30 · FY2025 · CA · contact PI
Leadership Planning and Evaluation$339,811
P30 · FY2025 · CA · contact PI
Core 3: Translational Pathology Shared Resource Core$27,884
U54 · FY2025 · CA · contact PI
Cancer Center Support Grant$7,263,544
P30 · FY2024 · CA · contact PI
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan$2,243,832
UH3 · FY2024 · CA
SPORE in Breast Cancer$896,275
P50 · FY2024 · CA
Developmental Funds$828,396
P30 · FY2024 · CA · contact PI
Leadership Planning and Evaluation$625,450
P30 · FY2024 · CA · contact PI
Immune Landscape of Anal Cancer and Survival Outcomes in People with HIV (Immuno/Microenvironment)$250,000
P30 · FY2024 · CA · contact PI
Evaluation of Radiomic and Blood-Based Biomarkers for the Early Detection of Lung Cancer in People Living with HIV (Biospecimen/Cohort)$250,000
P30 · FY2024 · CA · contact PI
Core 3: Translational Pathology Shared Resource Core$28,395
U54 · FY2024 · CA · contact PI
Cancer Center Support Grant$7,263,544
P30 · FY2023 · CA · contact PI
SPORE in Breast Cancer$2,181,491
P50 · FY2023 · CA
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan$1,936,770
UH3 · FY2023 · CA
Developmental Funds$828,396
P30 · FY2023 · CA · contact PI
Leadership Planning and Evaluation$625,450
P30 · FY2023 · CA · contact PI
Accelerated Aging and Anal Cancer Risk among People Living with HIV$257,182
P30 · FY2023 · CA · contact PI
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer$144,991
R01 · FY2023 · CA · contact PI
Clinical and Pathologic Response to Neoadjuvant Chemotherapy for Breast Cancer$125,000
P50 · FY2023 · CA
Core 3: Translational Pathology Shared Resource Core$27,325
U54 · FY2023 · CA · contact PI
Cancer Center Support Grant$7,271,076
P30 · FY2022 · CA · contact PI
SPORE in Breast Cancer$2,031,380
P50 · FY2022 · CA
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan$1,050,989
UG3 · FY2022 · CA
Developmental Funds$828,396
P30 · FY2022 · CA · contact PI
Leadership Planning and Evaluation$625,450
P30 · FY2022 · CA · contact PI
Accelerated Aging and Anal Cancer Risk among People Living with HIV$242,823
P30 · FY2022 · CA · contact PI
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer$228,659
R01 · FY2022 · CA · contact PI
Evaluation of Barriers to Completion of Breast Cancer Treatment at a Tertiary Teaching and Referral Center in Kenya$125,933
P50 · FY2022 · CA
Core 3: Translational Pathology Shared Resource Core$65,976
U54 · FY2022 · CA · contact PI
Cancer Center Support Grant$59,999
P30 · FY2022 · CA · contact PI
Cancer Center Support Grant$7,271,074
P30 · FY2021 · CA · contact PI
SPORE in Breast Cancer$2,153,378
P50 · FY2021 · CA
CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan$1,076,143
UG3 · FY2021 · CA
Building Research Capacity and Opportunities to Bring Cancer Prevention and Control Efforts to Persistent Poverty Areas in the South$200,000
P30 · FY2021 · CA · contact PI
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer$85,374
R01 · FY2021 · CA · contact PI
National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement for Fiscal Year (FY) 2021$59,999
P30 · FY2021 · CA · contact PI
Core 3: Translational Pathology Shared Resource Core$27,884
U54 · FY2021 · CA · contact PI
Circulating plasma tumor DNA as a biomarker for early stage breast cancer$364,039
R01 · FY2020 · CA · contact PI
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer$233,325
R01 · FY2020 · CA · contact PI
Circulating plasma tumor DNA as a biomarker for early stage breast cancer$353,116
R01 · FY2019 · CA · contact PI
Molecular Complete Response in Blood as a Predictor for a Pathologic Complete Response after Neoadjuvant Therapy fo Breast Cancer$226,326
R01 · FY2019 · CA · contact PI
Circulating plasma tumor DNA as a biomarker for early stage breast cancer$378,539
R01 · FY2018 · CA · contact PI
Molecular complete response in blood as a predictor for pathologic complete response after neoadjuvant therapy for breast cancer$224,662
R01 · FY2018 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$584,051
T32 · FY2017 · CA · contact PI
Circulating plasma tumor DNA as a biomarker for early stage breast cancer$374,482
R01 · FY2017 · CA · contact PI
Circulating plasma tumor DNA as a biomarker for early stage breast cancer$67,989
R01 · FY2017 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$473,978
T32 · FY2016 · CA · contact PI
Circulating plasma tumor DNA as a biomarker for early stage breast cancer$373,053
R01 · FY2016 · CA · contact PI
Molecular Targets for Cancer Detection and Treatment$498,117
T32 · FY2015 · CA
Molecular Targets for Cancer Detection and Treatment$39,754
T32 · FY2015 · CA
Molecular Targets for Cancer Detection and Treatment$552,512
T32 · FY2014 · CA
Molecular Targets for Cancer Detection and Treatment$45,674
T32 · FY2014 · CA
Molecular Targets for Cancer Detection and Treatment$601,428
T32 · FY2013 · CA
Molecular Targets for Cancer Detection and Treatment$467,852
T32 · FY2012 · CA
Molecular Targets for Cancer Detection and Treatment$513,531
T32 · FY2011 · CA
Genetic effectors of TGF-beta induced growth and arrest.$254,392
R01 · FY2010 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest.$254,392
R01 · FY2009 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest.$61,227
R01 · FY2009 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest.$254,392
R01 · FY2008 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest.$59,634
R01 · FY2008 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest$215,069
R01 · FY2007 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest.$58,033
R01 · FY2007 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest.$294,901
R01 · FY2006 · CA · contact PI
Genetic effectors of TGF-beta induced growth and arrest$100,000
R55 · FY2005 · CA